At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
Sunitinibdrug
Likely dose
Sunitinib 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Non-Small Cell Lung Cancer And Brain Metastases
In Brief
A Phase 2 clinical trial evaluating Sunitinib for Non-Small Cell Lung Cancer. Completed, enrolled 66 participants across 27 sites in 4 countries.
Detailed Summary
This study will evaluate the safety, tolerability and efficacy of SU011248 in patients with non-small cell lung cancer with brain metastases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesFrance, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartMar 2007
Primary CompletionDec 2009
TodayJul 2026
First PostedSep 7, 2006
Enrollment StartMar 1, 2007
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.8 years ago
Interventions
Sunitinibdrug
Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity